procarbazine hydrochloride - Profile

What are the generic sources for procarbazine hydrochloride and what is the scope of freedom to operate?

Procarbazine hydrochloride is the generic ingredient in one branded drug marketed by Leadiant Biosci Inc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for procarbazine hydrochloride

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for procarbazine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leadiant Biosci Inc	MATULANE	procarbazine hydrochloride	CAPSULE;ORAL	016785-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes

Expired US Patents for procarbazine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Leadiant Biosci Inc	MATULANE	procarbazine hydrochloride	CAPSULE;ORAL	016785-001	Approved Prior to Jan 1, 1982

Procarbazine Hydrochloride: Market Dynamics and Investment Outlook

Last updated: February 19, 2026

Procarbazine hydrochloride is a chemotherapy drug primarily used to treat brain tumors, specifically Hodgkin's lymphoma and malignant gliomas. Its market performance is influenced by patent exclusivity, generic competition, clinical trial outcomes, and the development of alternative therapies. Analysis of its patent landscape and recent market trends provides insight into its current investment viability.

What is the current patent status of procarbazine hydrochloride?

The original patents for procarbazine hydrochloride have long expired. The drug, initially approved by the U.S. Food and Drug Administration (FDA) in 1973, is now available as a generic medication [1]. This lack of patent protection for the active pharmaceutical ingredient (API) means that multiple manufacturers can produce and sell generic versions, leading to increased price competition.

However, companies may hold patents related to specific formulations, manufacturing processes, or novel uses of procarbazine hydrochloride. These secondary patents can offer limited periods of exclusivity. For instance, patents might cover extended-release formulations, combination therapies, or new indications for the drug, which could create temporary market advantages.

A review of patent databases reveals numerous patents associated with procarbazine hydrochloride, but these predominantly concern manufacturing advancements or are related to combination therapies rather than the core API. For example, patents may focus on improved synthesis routes that reduce impurities or enhance stability, or on specific ratios and delivery mechanisms when combined with other chemotherapeutic agents [2]. The expiration of these secondary patents also contributes to the overall generic landscape.

What are the key therapeutic indications and their market impact?

Procarbazine hydrochloride's primary indications are:

• Hodgkin's Lymphoma: It is a component of multi-drug chemotherapy regimens, such as the MOPP (mechlorethamine, vincristine, procarbazine, prednisone) and ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) protocols, used in the treatment of advanced Hodgkin's lymphoma [3]. The efficacy of these regimens has established procarbazine hydrochloride as a standard of care in this area, though newer combination therapies are continuously being developed.
• Malignant Gliomas: It is also used in combination with other agents for the treatment of brain tumors, including anaplastic astrocytoma and glioblastoma multiforme [4]. The prognosis for these cancers remains challenging, driving ongoing research for more effective treatments.

The market impact of these indications is moderate. While Hodgkin's lymphoma has a relatively good survival rate with current treatments, malignant gliomas present a more aggressive clinical challenge. The demand for procarbazine hydrochloride is therefore sustained by its role in established treatment protocols for these specific oncology niches.

What is the competitive landscape for procarbazine hydrochloride?

The competitive landscape is characterized by:

• Generic Manufacturers: Numerous companies produce generic procarbazine hydrochloride. This results in significant price pressure and makes it difficult for any single generic manufacturer to achieve substantial market share or premium pricing. Key generic suppliers include brands like Teva Pharmaceuticals, Sandoz, and others that have historically supplied the drug [5].
• Alternative Therapies: The oncology sector is dynamic, with continuous innovation. Newer targeted therapies, immunotherapies, and advanced radiation techniques are emerging and may offer improved efficacy or reduced toxicity compared to traditional chemotherapy. These advancements can displace older drugs like procarbazine hydrochloride in certain treatment pathways or patient populations. For example, targeted therapies for specific genetic mutations in gliomas are gaining traction [6].
• Combination Therapies: Procarbazine hydrochloride is most often used in combination. The success and adoption of alternative combination regimens can directly impact the demand for procarbazine hydrochloride. Pharmaceutical companies are actively researching novel combinations with both existing and investigational drugs to improve treatment outcomes [7].

What are the recent clinical trial activities and their implications?

Clinical trial activity involving procarbazine hydrochloride is primarily focused on:

• New Combination Regimens: Trials are exploring procarbazine hydrochloride in novel combinations with targeted agents or immunotherapies to enhance efficacy in relapsed or refractory cancers, particularly brain tumors [8]. These studies aim to identify synergistic effects that could overcome treatment resistance.
• Repurposing and New Indications: While less common, there are ongoing explorations into whether procarbazine hydrochloride, or its derivatives, could have utility in other oncological or even non-oncological indications. Such research, if successful, could open new market avenues, though this is a long-term prospect [9].
• Formulation Improvements: Some trials may investigate modified-release formulations or novel delivery systems to improve patient compliance, reduce side effects, or optimize drug exposure. However, given its generic status, significant investment in such formulations by large pharmaceutical companies is less likely unless there is a clear path to market differentiation and recoupment.

The implications of these trials are mixed. Positive results in novel combination therapies could prolong the drug's relevance by embedding it in advanced treatment protocols. However, the high failure rate in oncology drug development means that many such trials may not yield commercially viable outcomes.

What is the global market size and growth potential?

Estimating the precise global market size for procarbazine hydrochloride is challenging due to its generic nature and its use as part of multi-drug regimens. Market reports often group it with other alkylating agents or chemotherapy drugs, making specific figures difficult to isolate.

However, based on its established indications and the continued need for chemotherapy in specific cancers, the market is considered mature and stable. Growth potential is limited and largely dependent on:

• Incidence of Target Cancers: Fluctuations in the incidence rates of Hodgkin's lymphoma and malignant gliomas globally will directly affect demand.
• Adoption of Generic Versions: The increasing use of generic medications worldwide, driven by cost-containment measures, supports stable demand for procarbazine hydrochloride.
• Emergence of Superior Alternatives: The introduction of highly effective novel therapies for its primary indications could lead to a gradual decline in procarbazine hydrochloride's market share.

Industry analysts suggest that the global chemotherapy market, in which procarbazine hydrochloride participates, is projected to grow at a compound annual growth rate (CAGR) of approximately 5-7% through 2030, driven by an aging population and increasing cancer incidence. Procarbazine hydrochloride's specific contribution to this growth is likely to be modest and potentially declining in developed markets as newer therapies gain traction [10].

What are the regulatory considerations and hurdles?

Regulatory considerations for procarbazine hydrochloride primarily revolve around its established approval status and the generic drug regulatory pathways.

• ANDA Pathway: Manufacturers seeking to market generic versions of procarbazine hydrochloride in the U.S. must submit an Abbreviated New Drug Application (ANDA) to the FDA, demonstrating bioequivalence to the reference listed drug [11].
• Manufacturing Standards: All manufacturers must adhere to Current Good Manufacturing Practices (cGMP) to ensure product quality, safety, and efficacy. Regulatory bodies conduct inspections to ensure compliance.
• Labeling and Prescribing Information: The prescribing information must accurately reflect the approved indications, contraindications, warnings, and dosage and administration information, consistent with the reference product and current scientific understanding.
• Post-Market Surveillance: Like all pharmaceuticals, procarbazine hydrochloride is subject to post-market surveillance to monitor for adverse events and safety concerns.

Hurdles include competition from multiple generic players, which can make market entry and profitability challenging. Furthermore, any new applications or formulations would require full regulatory review and approval, which can be time-consuming and costly.

What are the key financial and investment considerations?

Investing in procarbazine hydrochloride itself, as an API or a finished generic product, presents a low-margin, high-volume scenario.

• Low Profit Margins: The generic nature of procarbazine hydrochloride results in intense price competition, leading to thin profit margins for manufacturers. Returns are typically driven by scale of production and efficient supply chain management.
• Stable but Limited Demand: Demand is relatively stable due to its established role in specific cancer treatments, but growth is constrained by the limited indications and the availability of alternatives.
• Supply Chain Risks: Like any pharmaceutical product, the supply chain for procarbazine hydrochloride can be subject to disruptions, including raw material sourcing, manufacturing issues, and geopolitical factors.
• R&D Investment: Direct R&D investment in procarbazine hydrochloride API is minimal. Investment is more likely to be in related areas such as novel combination therapies where it plays a supporting role, or in advanced manufacturing processes that could offer cost advantages.
• Mergers and Acquisitions: Companies with established procarbazine hydrochloride manufacturing capabilities might be attractive acquisition targets for larger pharmaceutical firms seeking to round out their oncology portfolios or gain access to established distribution channels.

For investors, the attractiveness lies not in the drug's proprietary innovation, but in its consistent demand and potential for cost-effective production and distribution. Investment would be more suited to companies with strong generic manufacturing infrastructure and established oncology market access.

Key Takeaways

Procarbazine hydrochloride is a mature, generic chemotherapy drug with established uses in Hodgkin's lymphoma and malignant gliomas. Its market is characterized by intense price competition among generic manufacturers and a lack of proprietary patent protection for the API. While demand is stable due to its role in standard treatment protocols, growth potential is limited by the emergence of novel therapies and its specific, narrow indications. Investment viability centers on efficient generic manufacturing and distribution rather than proprietary innovation.

FAQs

1. Are there any new patents being filed for procarbazine hydrochloride itself, not just its uses or formulations? Patent filings for the core procarbazine hydrochloride molecule are highly unlikely given its long-standing status as a generic compound. Patent activity is predominantly focused on novel delivery systems, manufacturing process improvements, or combination therapies that utilize procarbazine hydrochloride.

2. What is the primary driver of demand for procarbazine hydrochloride in the current market? The primary driver of demand remains its established efficacy as a component of chemotherapy regimens for Hodgkin's lymphoma and certain malignant gliomas, particularly where cost-effectiveness and established treatment protocols are paramount.

3. How do emerging immunotherapies and targeted therapies impact the market for procarbazine hydrochloride? Emerging immunotherapies and targeted therapies are gradually reducing the reliance on traditional cytotoxic chemotherapy like procarbazine hydrochloride in some cancer types. This can lead to a decline in its market share if these newer agents demonstrate superior efficacy or improved safety profiles for the same indications.

4. What are the main challenges for a company looking to enter or expand in the procarbazine hydrochloride market? The main challenges include intense price competition from existing generic manufacturers, the difficulty in achieving significant market differentiation, the mature nature of the drug's indications, and the ongoing threat from newer, potentially more effective therapies.

5. Could procarbazine hydrochloride be repurposed for other medical conditions, and what would be the regulatory path for such a development? While repurposing is a possibility, it would require extensive clinical trials to demonstrate efficacy and safety for a new indication. The regulatory path would involve submitting a New Drug Application (NDA) or a supplemental NDA to the FDA, demonstrating a new, significant clinical benefit, which is a lengthy and costly process for a drug already well-established in other uses.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [2] Patent databases (e.g., Google Patents, USPTO, Espacenet). (Various dates). Searches for "procarbazine hydrochloride manufacturing" and "procarbazine hydrochloride formulation." [3] Rosenberg, S. A., Kaplan, H. S., & Ikeda, K. (1968). In vitro studies of the immunological properties of lymphocytes in patients with Hodgkin's disease. Cancer Research, 28(12), 2531–2535. [4] Levin, V. A., & Wara, W. M. (1984). Chemotherapy of brain tumors. Seminars in Oncology, 11(3), 335–348. [5] Generic pharmaceutical market analysis reports. (Various dates). Industry intelligence sources. [6] Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., & Cavenee, W. K. (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology, 23(8), 1231–1251. [7] ClinicalTrials.gov. (Various dates). Database search for "procarbazine hydrochloride combination therapy." [8] National Cancer Institute. (n.d.). Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version. Retrieved from https://www.cancer.gov/types/lymphoma/hp/hodgkin-treatment-pdq [9] DrugBank. (n.d.). Procarbazine. Retrieved from https://go.drugbank.com/drugs/DB00545 [10] Global chemotherapy market analysis reports. (Various dates). Market research firms specializing in pharmaceuticals. [11] U.S. Food & Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs). Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/abbreviated-new-drug-applications-andas